We scan new podcasts and send you the top 5 insights daily.
Arrowhead's demonstration of over 80% tau knockdown in CSF signals that transferrin-mediated delivery is expanding beyond enzymes and antibodies into siRNA conjugates. Much like GalNAc revolutionized liver targeting, transferrin technology is maturing across multiple competitors to overcome blood-brain barrier penetration challenges.
The biggest obstacle holding back the entire RNA field, including mRNA and oligonucleotides, is the challenge of delivering these therapies beyond the liver. A breakthrough in novel delivery mechanisms is considered more critical for unlocking the modality's therapeutic potential than discovering new RNA molecules.
Recognizing that severe myotonic dystrophy involves CNS impairment, Arthex deliberately invested in a lipid conjugation delivery system for its RNA therapeutic. This strategic choice was made specifically to cross the blood-brain barrier, enabling the treatment of both muscular and neurological symptoms of the disease.
The historical difficulty of delivering biologics to the brain is being addressed by novel "brain shuttle" technologies. These platforms, which facilitate transport across the blood-brain barrier, are enabling new enzyme replacement therapies and even AAV-delivered biologics for CNS diseases like leukodystrophies.
While current RNAi therapies are successful, they almost exclusively target liver cells (hepatocytes). The industry is only at the beginning of its journey. The real, massive opportunity lies in cracking the delivery challenge to target other cells, tissues, and organs with unmet medical needs.
Bio Arctic's "brain transporter" technology is differentiated from competitors. By carefully selecting where its antibody binds on the transferrin receptor, it avoids impacting red blood cells (reticulocytes). This preclinical finding suggests a better safety profile, a key competitive advantage that likely attracts major pharma partners.
After several tau-targeting antibodies failed, including J&J's pazdenimab, confidence in blocking extracellular tau is waning. The field's new hope is Biogen’s Biv80, an antisense drug that prevents tau protein production at the mRNA level, a mechanism that has shown potential to reverse pathology in early data.
Biogen's Phase 2 data for BIV80 is pivotal because its antisense mechanism targets Tau at the mRNA level, reducing all forms of the protein. This "turns off the faucet" approach provides a broad, definitive test of whether targeting Tau itself is a viable strategy for Alzheimer's, bypassing the complexity of its various forms.
Bio Arctic is strategically expanding its brain transporter platform beyond its initial focus. It's now being applied to new modalities like enzymes, ASOs, and siRNAs, and is venturing outside of neurology into oncology through a partnership for glioblastoma. This demonstrates the technology's broad applicability.
The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.
CNS therapeutic delivery is a multi-layered hierarchy rather than just crossing the blood-brain barrier. Effective delivery requires achieving adequate exposure in specific anatomical brain regions, verifying target engagement within precise cell types, and achieving proper intracellular trafficking for advanced modalities like ASOs, siRNAs, and AAVs.